Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach

医学 赛马鲁肽 耐受性 安慰剂 药代动力学 肥胖 药品 药物开发 药理学 不利影响 内科学 安全概况 减肥 临床试验 减肥 体重 药品审批 药物治疗 药效学 超重
作者
Anders Strathe,Eric Morris Bomberg,Garrit Jensch,Jonas Kildegaard,Nina Majlund Harder-Lauridsen,Daniel Weghuber,Rune Viig Overgaard
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:28 (6): 4926-4934 被引量:4
标识
DOI:10.1111/dom.70678
摘要

AIMS: Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model-informed drug development (MIDD) to evaluate whether a 1.7-mg maintenance dose provides comparable exposure, tolerability and BMI effects in adolescents versus adults and versus the 2.4-mg dose. MATERIALS AND METHODS: Simulation analyses combined pharmacokinetic, BMI and safety data from the adolescent STEP TEENS Phase 3 study (N = 201) and the adult semaglutide STEP studies (Phases 2-3; ~3100 participants). Data across doses (0.25-2.4 mg) were used to model concentration-time profiles, extrapolate percent change in BMI for 1.7 mg, estimate proportions achieving ≥ 5%, ≥ 10% and ≥ 15% BMI reductions and predict gastrointestinal adverse event (AE) incidence as a function of exposure. RESULTS: Modelled semaglutide concentrations over 68 weeks were similar between adolescents and adults; body weight was the main covariate influencing exposure. For adolescents, the 1.7-mg dose showed comparable efficacy to 2.4 mg (mean BMI change: -15.2% vs. -17.4%) and was significantly greater than placebo (p < 0.01). Predicted proportions achieving prespecified BMI reduction thresholds and gastrointestinal AE profiles were similar across populations and doses. CONCLUSIONS: PK/PD and safety modelling indicated 1.7 mg semaglutide provides comparable exposure, tolerability and meaningful BMI reduction in adolescents versus adults and versus 2.4 mg. These results supported approval of 1.7 mg for adolescents ≥ 12 years in the November 2024 Wegovy label, obviating a dedicated adolescent 1.7-mg placebo trial.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
vc的应助被suer采纳,获得30
2秒前
兔兔兔兔兔完成签到,获得积分10
2秒前
花谢完成签到 ,获得积分10
2秒前
Marksman497发布了新的文献求助10
3秒前
勤奋甜瓜完成签到 ,获得积分10
4秒前
5秒前
坦率灵槐完成签到,获得积分10
5秒前
5秒前
璇璇完成签到,获得积分10
5秒前
lxf完成签到,获得积分10
7秒前
烂漫元彤发布了新的文献求助10
7秒前
传奇3的应助被yebo采纳,获得10
7秒前
赘婿的应助被九号球采纳,获得10
8秒前
DW的应助被麦粑块采纳,获得10
8秒前
Orange的应助被十点熄灯采纳,获得10
8秒前
zkylh的应助被麦粑块采纳,获得10
8秒前
bkagyin的应助被麦粑块采纳,获得10
9秒前
科研通AI6.3的应助被麦粑块采纳,获得10
9秒前
桐桐的应助被麦粑块采纳,获得10
9秒前
秋风的应助被麦粑块采纳,获得10
9秒前
领导范儿的应助被麦粑块采纳,获得10
9秒前
饺饺者完成签到,获得积分10
11秒前
11秒前
啦啦啦发布了新的文献求助10
12秒前
生半夏发布了新的文献求助10
12秒前
JvvJ完成签到 ,获得积分10
12秒前
13秒前
一颗苹果的应助被牧百川采纳,获得10
14秒前
14秒前
顾矜的应助被Swuliu采纳,获得10
15秒前
15秒前
15秒前
Ava的应助被科研通管家采纳,获得10
16秒前
JamesPei的应助被科研通管家采纳,获得10
16秒前
NexusExplorer的应助被科研通管家采纳,获得10
16秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183381
求助须知:如何正确求助?哪些是违规求助? 9572627
关于积分的说明 21826833
捐赠科研通 7780405
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558177
邀请新用户注册赠送积分活动 2480309